Pacific Biosciences of California (NASDAQ:PACB) Price Target

Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its target price decreased by Morgan Stanley from $10.00 to $4.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock. PACB has been the subject of a number of other […]

Related Keywords

California , United States , Davidw Meline , Pacific Biosciences , Piper Sandler , Oene Mark Van , Decheng Capital , California Inc , Edmond De Rothschild Holding , Securities Exchange Commission , Jpmorgan Chase Co , Morgan Stanley , Vanguard Group Inc , Investment Management , Goldman Sachs Group , Free Report , Get Free Report , Exchange Commission , Director David , Investors Weigh In On Pacific Biosciences , California Daily ,